Find Diisopropanolamine manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

API Suppliers

API Suppliers

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

0 DRUGS IN DEVELOPMENT

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

API REF. PRICE (USD/KG)

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Regulatory FDF Prices

NA

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

0

API

0

FDF

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

0

News #PharmaBuzz

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 110-97-4, Bis(2-hydroxypropyl)amine, 1,1'-iminodipropan-2-ol, Bis(2-propanol)amine, 1,1'-iminodi-2-propanol, 2-propanol, 1,1'-iminobis-
Molecular Formula
C6H15NO2
Molecular Weight
133.19  g/mol
InChI Key
LVTYICIALWPMFW-UHFFFAOYSA-N
FDA UNII
0W44HYL8T5

Diisopropanolamine
1 2D Structure

Diisopropanolamine

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
1-(2-hydroxypropylamino)propan-2-ol
2.1.2 InChI
InChI=1S/C6H15NO2/c1-5(8)3-7-4-6(2)9/h5-9H,3-4H2,1-2H3
2.1.3 InChI Key
LVTYICIALWPMFW-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CC(CNCC(C)O)O
2.2 Other Identifiers
2.2.1 UNII
0W44HYL8T5
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Bis(2-hydroxypropyl)amine

2. Diisopropanolamine Hydrochloride

2.3.2 Depositor-Supplied Synonyms

1. 110-97-4

2. Bis(2-hydroxypropyl)amine

3. 1,1'-iminodipropan-2-ol

4. Bis(2-propanol)amine

5. 1,1'-iminodi-2-propanol

6. 2-propanol, 1,1'-iminobis-

7. Di-2-propanolamine

8. Di-isopropanolamine

9. Dipa (alcohol)

10. Dipropyl-2,2'-dihydroxy-amine

11. 1-(2-hydroxypropylamino)propan-2-ol

12. N,n-bis(2-hydroxypropyl)amine

13. 1,1'-iminobis-2-propanol

14. 2-propanol, 1,1'-iminodi-

15. Diisopropanolamin

16. 1-[(2-hydroxypropyl)amino]propan-2-ol

17. Nsc 4963

18. Nsc-4963

19. 1,1'-iminobis[2-propanol]

20. 0w44hyl8t5

21. Dsstox_cid_179

22. Dsstox_rid_75418

23. Dsstox_gsid_20179

24. 1335-54-2

25. 1,1'-iminobis(2-propanol)

26. 1,1'-azanediylbis(propan-2-ol)

27. Cas-110-97-4

28. Ccris 6234

29. Hsdb 338

30. Einecs 203-820-9

31. Di-isopropanol Amine

32. Brn 0605363

33. Unii-0w44hyl8t5

34. 2-propanol,1,1'-iminobis-

35. Dipa Alcohol

36. Diiso-propanolamine

37. Diisopropanol Amine

38. Mfcd00004531

39. Di(2-hydroxypropyl)amine

40. 2-propanol,1'-iminodi-

41. 2-propanol,1'-iminobis-

42. Bis-(2-hydroxypropyl)amine

43. Ec 203-820-9

44. Bis-(2-hydroxypropyl)-amine

45. Schembl22774

46. 3-04-00-00761 (beilstein Handbook Reference)

47. 1,1'-azanediyldipropan-2-ol

48. Di(2-hydroxy-n-propyl) Amine

49. Diisopropanolamine [ii]

50. Diisopropanolamine [mi]

51. 1,1'-imino-di(2-propanol)

52. Chembl2106303

53. Dtxsid8020179

54. 1,1'-azanediylbis Propan-2-ol

55. Diisopropanolamine [hsdb]

56. Diisopropanolamine [inci]

57. 1,1'-azanediyldi(propan-2-ol)

58. Diisopropanolamine [vandf]

59. Nsc4963

60. Chebi:143266

61. Wln: Qy1 & 1m1yq1

62. Diisopropanolamine [mart.]

63. Albb-005923

64. Amy25531

65. Tox21_201602

66. Tox21_302859

67. 2-propanol, 1,1'-iminobis-, N-(hydrogenated Tallow Alkyl) Derivs.

68. Bbl013266

69. Stk503623

70. Akos005457854

71. Dipa Low Freeze Grade 85 (salt/mix)

72. Dipa Low Freeze Grade 90 (salt/mix)

73. Ncgc00249081-01

74. Ncgc00256476-01

75. Ncgc00259151-01

76. 68153-96-8

77. Vs-03726

78. Diisopropanolamine (dl- And Meso- Mixture)

79. Bis(2-hydroxypropyl)amine, >=98.0% (t)

80. D0924

81. Q777543

82. J-660021

83. F0001-0230

84. 9afd2c98-2177-4499-8eb2-1c8ea079f21d

2.4 Create Date
2005-03-26
3 Chemical and Physical Properties
Molecular Weight 133.19 g/mol
Molecular Formula C6H15NO2
XLogP3-0.8
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count3
Rotatable Bond Count4
Exact Mass133.110278721 g/mol
Monoisotopic Mass133.110278721 g/mol
Topological Polar Surface Area52.5 Ų
Heavy Atom Count9
Formal Charge0
Complexity60.1
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count2
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Pharmacology and Biochemistry
4.1 Absorption, Distribution and Excretion

19.5 mg/kg (14)C-DIPA in acetone /was applied dermally/ to an area of skin on the shoulder of four female Fisher 344 rats. After evaporation of the solvent /site of application remained covered for 48 hr/. At 48 hr 25% of the substance had penetrated the skin (12% excreted in the urine, 1% excreted in the feces and expired air, 12.5% remaining in the tissue and 73% was recovered from the application site and surroundings.

European Chemicals Bureau; IUCLID Dataset, diisopropanolamine (110-97-4) (2000 CD-ROM edition). Available from, as of September 19, 2005: https://esis.jrc.ec.europa.eu/


When 4 female Fischer-344 rats were injected iv with 19 mg (14)C-labelled diisopropanolamine in aqueous solution, more than 70% of the radioactivity was eliminated from the blood during the first 6 hr. About 90% of the dose was recovered from the urine within 12 hours.

Institution for Statutory Accident Insurance and Prevention in the Chemical Industry (Berufsgenossenschaft der chemischen industrie); Toxicological Evalution No. 178 Diisopropanolamine p.175 (1991)


Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more
Excipient Market Overview: Roquette, Seqens, Evonik make strategic moves; new guidelines deal with contamination
The pharmaceutical industry has long recognized the critical role excipients or inactive ingredients play in drug formulation and delivery. Excipients can comprise up to 90 percent of a medicine's total ingredients and serve crucial functions as binders, disintegrants, coatings, preservatives, colors, and flavorings. According to recent market research, the pharmaceutical excipients market was valued at US$ 9.27 billion in 2023. It is growing at a compound annual growth rate (CAGR) of 7.03 percent and is projected to reach US$ 18.48 billion by 2032. The main factors driving market growth is an increased demand for multifunctional excipients, coupled with the expanding use of generic medications. The development in the biologics sector and advancements in nanotechnology are also contributing significantly to market growth. Major excipient providers include BASF, Evonik, Merck KGaA owned MilliporeSigma, Gangwal Healthcare, Roquette Frères, DuPont, Croda International, Seqens, Boai NKY Pharmaceuticals, PMC Isochem, Minakem, Kewpie Corporation, Ashland Global, SPI Pharma, Pfanstiehl, Nanjing Well Pharmaceutical, ICE Pharma, Anhui Ribobay Pharmaceutical and Nippon Fine Chemical.  View Our Dashboard on Major Excipient Companies in 2024 (Free Excel Available) WHO, India’s CDSCO tighten regulations; new GMP guidelines implemented to curb contamination Last year, the World Health Organization (WHO) issued a health alert linking at least 300 child deaths in the Gambia, Uzbekistan, and Indonesia to the ingestion of contaminated cough syrups containing unacceptable levels of diethylene glycol (DEG) and ethylene glycol (EG). In response to the tragic events, the WHO released two draft appendices to its guideline on good manufacturing practices (GMPs) for excipients this year. Manufacturers are now required to use suitable risk assessment tools to identify and mitigate potential hazards.  Since India-made cough syrups had been linked to the deaths, India’s drug regulator — Central Drugs Standard Control Organization (CDSCO) — took steps to prevent contamination, and advised drugmakers to only use pharmaceutical-grade excipients from approved sources. Furthermore, the Indian Health Ministry proposed amendments to the Drugs and Cosmetics Rules, 1945 to include details of excipients on drug labels. While listing all excipients on every strip of medicine may be challenging, the ministry suggested mentioning those causing hypersensitivity on the label. Applicants now mandatorily need to submit evidence of stability and safety of excipients. These regulatory developments have significant implications for excipient manufacturers and pharmaceutical companies worldwide. Leading pharmaceutical excipient firms like Gangwal Healthcare, Sigachi Industries, and Nitika Pharmaceuticals are well-positioned to meet these heightened quality and safety standards, given their long-standing commitment to producing high-quality, compliant excipients.  View Our Dashboard on Major Excipient Companies in 2024 (Free Excel Available)   Roquette buys IFF’s pharma unit for US$ 2.85 bn; Evonik opens new spray-drying facility in Darmstadt In a significant industry move, France-based Roquette entered into an agreement to acquire IFF's pharma solutions business in a deal valued at US$ 2.85 billion. This acquisition is set to rebalance family-owned Roquette’s portfolio around health and nutrition. The deal is expected to accelerate Roquette’s growth and significantly strengthen its presence in the excipients market. Evonik has opened a new facility for drying aqueous dispersions of its Eudragit polymers at its site in Darmstadt, Germany. The facility will help Evonik meet increasing demand from drugmakers for its oral drug delivery solutions. The plant uses green energy solutions. The company has also partnered University of Mainz to commercialize a new class of polyethylene glycols (PEG) lipids for nucleic acid delivery. Evonik’s Health Care business has been growing its nucleic acid drug and vaccine delivery portfolio.  Germany’s Johannes Gutenberg University of Mainz was the first to develop randomized polyethylene glycols (rPEGs). This collaboration aims to expand Evonik’s toolbox of technologies for nucleic acid-based medicines, offering an improved immunogenicity profile for lipid nanoparticle carriers used in mRNA vaccines and therapeutics. Asahi Kasei made significant strides in addressing a pressing industry concern that emerged in 2018 when potentially carcinogenic nitrosamine impurities were detected in several pharmaceuticals. Guided by regional authorities, such as the European Medicines Agency and the US Food and Drug Administration, the pharmaceutical industry has been carrying out extensive assessments and research to identify the cause of these impurities. In response to this challenge, Asahi Kasei developed its Ceolus microcrystalline cellulose with extremely low nitrite levels. The Japanese company achieved nitrite concentrations of 0.1 micrograms per gram or less, which is equivalent to 0.1 parts per million (ppm). The company also started full commercial operation of its second manufacturing facility for Ceolus in Japan, enhancing supply capacity and stability. JRS Pharma and Gujarat Microwax opened a state-of-the-art cotton-based croscarmellose sodium plant in Mehsana, Gujarat (India). This facility aims to produce high-quality excipients that meet global standards, potentially reducing India's dependency on imports and boosting its presence in the global excipient market. The Indian excipient industry accounts for less than 1 percent of the global market share.  View Our Dashboard on Major Excipient Companies in 2024 (Free Excel Available)   Seqens to advance innovative polymer; biologics, personalized medicine create demand for specialized excipients Recent industry collaborations highlight the ongoing innovation in novel excipients. France’s Seqens, with over 20 years of polymer development experience, was chosen by Pleryon Therapeutics to advance its leading osteoarthritis candidate – an innovative GMP polymer. This collaboration leverages Seqens’ newly expanded and modernized cGMP plant in Aramon, France, demonstrating the industry’s commitment to investing in advanced manufacturing capabilities for novel excipients.  The rise of biologics and personalized medicine has created a demand for specialized excipients capable of stabilizing complex molecules and enabling targeted drug delivery. Roquette’s launch of Lycagel Flex, a hydroxypropyl pemix for nutraceutical and pharmaceutical softgel capsules, exemplifies this trend. Built on Roquette’s market-first Lycagel pea starch technology, this plant-based alternative to gelatin offers manufacturers the flexibility to customize formulations for a range of production and end-user needs. The innovative pea starch foundation also underscores the industry’s move towards sustainable bio-based excipients. The trend towards patient-centric drug development has also influenced excipient innovation. Excipients that can improve palatability, ease of swallowing, or enable novel dosage forms (such as orally disintegrating tablets) are in high demand. For example, IFF brought a super disintegrant Ac-Di-Sol, that supports faster disintegration and drug dissolution in oral disintegrating tablets, improving patient experience.  View Our Dashboard on Major Excipient Companies in 2024 (Free Excel Available)   Our view The heightened regulatory scrutiny on excipients due to product contamination incidents has created a high risk perception and uncertainty around the regulatory acceptance of novel excipients. That said, novel excipients are central to the development of new drug modalities and therapies. Going forward, sustainability will also become an increasingly important factor in excipient selection and development. As the industry innovates towards biologics, personalized therapies, and patient-centric formulations, the role of high-quality, multifunctional excipients will only grow more vital in ensuring drug stability, bioavailability, and patient compliance. Companies that can navigate the complex regulatory landscape, invest in R&D, and offer high-quality, multifunctional excipients will be well-positioned to succeed in this evolving market.   

Impressions: 3134

https://www.pharmacompass.com/radio-compass-blog/excipient-market-overview-roquette-seqens-evonik-make-strategic-moves-new-guidelines-deal-with-contamination

#PharmaFlow by PHARMACOMPASS
12 Sep 2024

ABOUT THIS PAGE

Looking for 110-97-4 / Diisopropanolamine API manufacturers, exporters & distributors?

Diisopropanolamine manufacturers, exporters & distributors 1

32

PharmaCompass offers a list of Diisopropanolamine API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Diisopropanolamine manufacturer or Diisopropanolamine supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Diisopropanolamine manufacturer or Diisopropanolamine supplier.

PharmaCompass also assists you with knowing the Diisopropanolamine API Price utilized in the formulation of products. Diisopropanolamine API Price is not always fixed or binding as the Diisopropanolamine Price is obtained through a variety of data sources. The Diisopropanolamine Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Diisopropanolamine

Synonyms

110-97-4, Bis(2-hydroxypropyl)amine, 1,1'-iminodipropan-2-ol, Bis(2-propanol)amine, 1,1'-iminodi-2-propanol, 2-propanol, 1,1'-iminobis-

Cas Number

110-97-4

Unique Ingredient Identifier (UNII)

0W44HYL8T5

Diisopropanolamine Manufacturers

A Diisopropanolamine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Diisopropanolamine, including repackagers and relabelers. The FDA regulates Diisopropanolamine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Diisopropanolamine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

Diisopropanolamine Suppliers

A Diisopropanolamine supplier is an individual or a company that provides Diisopropanolamine active pharmaceutical ingredient (API) or Diisopropanolamine finished formulations upon request. The Diisopropanolamine suppliers may include Diisopropanolamine API manufacturers, exporters, distributors and traders.

Diisopropanolamine GMP

Diisopropanolamine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Diisopropanolamine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Diisopropanolamine GMP manufacturer or Diisopropanolamine GMP API supplier for your needs.

Diisopropanolamine CoA

A Diisopropanolamine CoA (Certificate of Analysis) is a formal document that attests to Diisopropanolamine's compliance with Diisopropanolamine specifications and serves as a tool for batch-level quality control.

Diisopropanolamine CoA mostly includes findings from lab analyses of a specific batch. For each Diisopropanolamine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Diisopropanolamine may be tested according to a variety of international standards, such as European Pharmacopoeia (Diisopropanolamine EP), Diisopropanolamine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Diisopropanolamine USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty